Summary
Safe, effective treatment is available for acute crystal-associated arthropathy. It is time for some older remedies, phenylbutazone and perhaps colchicine, to give way to more modern regimens of combined NSAID therapy and intra-articular steroid injection. Hypouricaemic agents have revolutionised the management of gout but are not without their dangers, and there is a need for re-emphasis on the value of dietary measures and control of alcohol and diuretic use. At present only symptomatic management is available for chronic pyrophosphate- and hydroxyapatite-associated disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bunning RD, Barth WF. Sulindac: a potentially renal sparing non-steroidal anti-inflammatory drug. Journal of the American Medical Association 248: 2864–2867, 1982
Dieppe PA, Calvert P. Treatment. In Crystals and joint disease, pp. 240–254, Chapman and Hall, London, 1983
Dieppe PA, Doherty M. The role of particles in the pathogenesis of joint disease. In Berry (Ed.) Current topics in pathology: bone and joint disease, pp. 199–233, Springer-Verlag, New York, 1982
Dieppe PA, Doherty M, Macfarlane DG, Hutton CW, Bradfield JW, et al. Apatite associated destructive arthritis. British Journal of Rheumatology 23: 84–91, 1984
Doherty M Potential rheumatological applications of intra-articular radiocolloid therapy. Geriatric Medicine Today 3: 31–42, 1984
Doherty M, Dieppe PA. Double blind placebo-controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy. Annals of the Rheumatic Diseases 42 (Suppl.): 106–107, 1983
Doherty M, Dieppe PA. Crystal deposition disease in the elderly. Clinics in Rheumatic Diseases 12(1): 97–116, 1986
Emmerson BT. Therapeutics of hyperuricaemia and gout. Medical Journal of Australia 141: 31–36, 1984
Faires JS, McCarty DJ. Acute arthritis in man and dog after intrasynovial injection of sodium urate crystals. Lancet 2: 682–685, 1962
Fam AG, Paton TW, Chaiton A. Reinstitution of allopurinol therapy for gouty arthritis after cutaneous reactions. Canadian Medical Association Journal 123(2): 128–129, 1980
Hart FD, Huskisson T. Non-steroidal anti-inflammatory drugs: current status and rational therapeutic use. Drugs 27(3): 232–255, 1984
Liang MH, Fries JF. Asymptomatic hyperuricaemia: the case for conservative management. Annals of Internal Medicine 88: 666–670, 1978
McCarty DJ. Crystal induced inflammation; syndromes of gout and pseudogout. Geriatrics 18: 467–478, 1963
McCarty DJ. Calcium pyrophosphate crystal deposition disease: pseudogout: articular chondrocalcinosis. In Hollander JL (Ed.) Arthritis and allied conditions, 9th ed., pp. 51–69, Lea & Febiger, Philadelphia, 1979
McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Annals of Internal Medicine 54: 452–460, 1961
Roberts WN, Liang MH, Stern SH. Colchicine in acute gout; reassessment of risks and benefits. Journal of the American Medical Association 257(14): 1920–1922, 1987
Templeton JS. Azapropazone or allopurinol in the treatment of chronic gout and/or hyperuricaemia: a preliminary report. British Journal of Clinical Practice 36(10): 353–358, 1982
Terkeltaub RA, Ginsberg MH. The inflammatory reaction to crystals. In McCarty DJ (Ed.) Rheumatic disease clinics of North America: crystal deposition diseases. Vol. 14 (2), WB Saunders, Philadelphia, 1988
Yu TF. Diversity of clinical features in gouty arthritis. Seminars in Arthritis and Rheumatism 13(4): 360–368, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arie, E., Doherty, M. Crystal-Associated Rheumatic Disease. Drugs 37, 566–576 (1989). https://doi.org/10.2165/00003495-198937040-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198937040-00008